Japan· JP-2699704M3028

ヨウ素

A iodine product containing ヨウ素, registered in Japan by スミス・アンド・ネフュー, on the national reimbursement list. The same ATC class is registered in 7 of our 19 countries.

On Japan’s NHI price listATC D08AG03

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedヨウ素ATCD08AG03REGISTER NO.JP-2699704M3028PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Iodine is registered in 7 of 19 countries.

Countries holding a registration under ATC D08AG03 (iodine), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 4 of them publish a price we can compare per daily dose

Iodine · ATC D08AG03

7 / 19 countries

  • Belgiumprice
  • Ireland
  • Japan
  • Norwayprice
  • Spainprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ヨウ素
Manufacturer
スミス・アンド・ネフュー
Country
Japan (JP)
ATC code
D08AG03
ATC class
Iodine
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for iodine.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Iodine · interactions on record

1 record

  • 1 moderate

Most severe, free to view

  • LithiumN05AN01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Iodine in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All iodine products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Bulgaria · Етанолов Разтвор На Йод Bt, Етанолов Разтвор На Йод Купро
  • Czechia · Lipiodol Ultra Fluide
  • Germany · Iod Caelo
  • Denmark · Omnipaque
  • Estonia · Iodine Valentis, Solutio Iodi Spirituosa
  • Spain · Tintura De Yodo Laboratorios Reig Jofré S.A.
  • Greece · Βαμμα Ιωδιου Mediplants, Βαμμα Ιωδιου Ζαρμπη
  • Croatia · Jod B. Braun
  • Lithuania · Jodas Bp, Jodas Valentis
  • Latvia · Joda Šķīdums Valentis, Joda Spirta Šķīdums
  • Poland · Jodid, Jodyna

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/27ef224d-84e2-482b-b8d7-2ab21d78173d
GET /v1/drugs/27ef224d-84e2-482b-b8d7-2ab21d78173d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "0.9%1g",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2699704M3028",
  "category": "外用薬",
  "price_yen": 50.2,
  "generic_name": "ヨウ素",
  "product_name_jp": null,
  "therapeutic_class": "2699",
  "transitional_expiry": null
}

See everything about iodine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.